| Autor: |
X L, Bai, X, Li, T B, Liang |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Zhonghua wai ke za zhi [Chinese journal of surgery]. 58(7) |
| ISSN: |
0529-5815 |
| Popis: |
Neoadjuvant therapy has been proved beneficial in patients with non-metastatic pancreatic cancer and it has received unprecedented attention in past years. However, the clinical value of neoadjuvant therapy in resectable pancreatic cancer patients remains controversial.Although the NCCN guideline has recommended that resectable pancreatic cancer patients with high-risk factors should be given preoperative neoadjuvant therapy, there is no consensus on specific criteria, treatment options, treatment duration and timing of surgery.More high-level evidences are strongly required.Recently, the development of new technologies such as liquid biopsy and radiomics analysis for pancreatic cancer will also help to address some clinical problems.This article reviewed the developments and controversies in neoadjuvant therapy for resectable pancreatic cancer.越来越多的研究结果证实，新辅助治疗能改善非转移性胰腺癌患者预后，因而新辅助治疗在胰腺癌治疗中的应用也受到了前所未有的重视，但其在可切除胰腺癌中的价值仍然存在争议。虽NCCN指南已推荐具有高危因素的可切除胰腺癌患者优先进行新辅助治疗，但对具体标准、治疗方案、用药周期及手术时机选择尚无共识，仍需要更多高等级循证医学证据做支撑。近年来胰腺癌液体活检及影像组学等新技术的发展也将有助于解决现有的一些临床问题。本文围绕可切除胰腺癌新辅助治疗有关研究进展进行阐述，并对目前的焦点问题进行讨论。. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
